EXENATIDE AND LIRAGLUTIDE – SIDE
EFFECTS. COMPARATIVE CLINICAL STUDY
LUMINIŢA TIMOFTE1,2, BERND STRATMANN1, WULF
QUESTER1, MARIUS TRAIAN BOJIŢĂ2, DIETHELM TSCHOEPE1*
1Heart and Diabetes Center NRW, Ruhr University Bochum, Georgstraβe
11, 32545, Bad Oeynhausen, Germany
2University of Medicine and Pharmacy „Iuliu Hatieganu“, Faculty of
Pharmacy, Victor Babes 8, RO-400012, Cluj-Napoca, Romania
*corresponding author: diethelm.tschoepe@ruhr-uni-bochum.de
Download Full Article

Abstract:

The objective of this study was to monitor the side effects of two agonists of
GLP-1 (glucagon-like peptide 1), exenatide and liraglutide, in order to determine their safety, tolerability and therapeutic efficiency. The study took place in the Heart and Diabetes Center NRW, Germany and overweight patients with type 2 diabetes whose therapeutic regimen was switched to incretin mimetics were included. A validated questionnaire method was used to monitor the side effects during the hospitalization period,
then again at 3, respectively 6 months after the beginning of the treatment.
The therapy with liraglutide was associated with fewer side effects than the one with exenatide. In general, side effects were declining with time, thus, only few patients stopped the treatment. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.

Top